Company · CIK 0001782223 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Pyxis Oncology, Inc. · PYXS
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 SForm 4 → | Jul 2, 4:30 pm EDT | Jakob DupontDirector | 35,000 | $3.06 | $107,100 | 38,741 | −47.5% | 10b5-1 |
| Jun 30, 2026 MForm 4 → | Jul 2, 4:30 pm EDT | Jakob DupontDirector | 35,000 | $1.60 | $56,000 | 73,741 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 AForm 4 → | Sep 8, 7:41 am EDT | Thomas CivikCEO & Chairman of the Board, Director | 2,503,050 | — | — | 2,503,050 | — | |
| Aug 20, 2026 AForm 4 → | Aug 20, 6:18 pm EDT | Jakob DupontDirector | 46,000 | — | — | 46,000 | — | |
| Aug 12, 2026 AForm 4 → | Aug 14, 4:06 pm EDT | Thomas CivikInterim CEO, Director | 250,956 | — | — | 941,087 | — | |
| Jun 30, 2026 MForm 4 → | Jul 2, 4:30 pm EDT | Jakob DupontDirector | 35,000 | — | — | 357,461 | — | 10b5-1 |